|
 Last year, Idorsia got a $5 million payment for a licensing option
for ACT-709478, but kept Neurocrine's identity a secret.
Their agreement calls for Idorsia to get $45 million in cash, $7
million for research and up to $365 million in development and
regulatory milestone payments if Neurocrine exercises its option
within 30 days of the U.S. Food and Drug Administration's accepting
an investigational new drug application that is now expected for
mid-2020.
Royalties are also in the offing if ACT-709478 makes it to market.
Idorsia Chief Executive Jean-Paul Clozel is striking agreements with
partners like Neurocrine, a small drugmaker based in San Diego, for
some of his pipeline's dozen investigational medicines.
[to top of second column] |
He is augmenting his coffers as he tries to build Idorsia into
another Actelion, the Swiss biotech Clozel sold in 2017 to Johnson &
Johnson for $30 billion.
ACT-709478, designed to target calcium channels throughout the
central nervous system believed to play a role in epilepsy, has
completed an early safety study in healthy adults and is slated to
start a Phase 2 trial in rare paediatric epilepsy this year.
"We are excited to leverage the scientific expertise of Idorsia in
T-type calcium channel inhibition to potentially advance a Phase 2
ready compound to help people suffering from epilepsy," Neurocrine
CEO Kevin Gorman said in a statement.
(Reporting by John Miller; Editing by Michael Shields)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
